Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma

Ioannis Ntanasis-Stathopoulos, Maria Douka, Vassilis Koutoulidis, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Irene Solia, Nikolaos Kanellias, Efstathios Kastritis, Meletios Dimopoulos, Evangelos Terpos, Lia-Angela Moulopoulos

Blood (2024) 144 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2024-209797

Published: 2024

Journal Articles

Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes

Maria Gavriatopoulou, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Maria Douka, Vasiliki Spiliopoulou, Charalampos Filippatos, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos, Lia-Angela Moulopoulos

Blood (2024) 144 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2024-209637

Published: 2024

Journal Articles

A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, Panagiotis Malandrakis, Pantelis Rousakis, Chrysanthi Panteli, Evangelos Eleutherakis-Papaiakovou, Vasiliki Spiliopoulou, Georgia Dimitrakopoulou, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Nikolaos Kanellias, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 490.

https://doi.org/10.1182/blood-2024-194090

Published: 2024

Journal Articles

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Efstathios Kastritis, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 7021.

https://doi.org/10.1182/blood-2024-203941

Published: 2024

Journal Articles

Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Panagiotis Malandrakis, Alexandros Briasoulis, Charalampos Filippatos, Despina Fotiou, Magdalini Migkou, Vasiliki Spiliopoulou, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 6968.

https://doi.org/10.1182/blood-2024-202627

Published: 2024

Journal Articles

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

Despina Fotiou, Foteini Theodorakakou, Irene Solia, Maria Gavriatopoulou, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2024-203853

Published: 2024

Journal Articles

Bone Disease Burden Does Not Seem to Impact Overall Survival in Newly Diagnosed Patients with Multiple Myeloma - a Detailed Imaging Analysis on 119 Patients

Evangelos Terpos, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, Stylianos Mavropoulos-Papoudas, Maria Douka, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Lia-Angela Moulopoulos, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 6941.

https://doi.org/10.1182/blood-2024-209786

Published: 2024

Journal Articles

Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group

Evangelos Terpos, Efstathios Kastritis, Sosana Delimpasi, Maria Kotsopoulou, Konstantina Papathanasiou, Vasiliki Labropoulou, Eirini Katodrytou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2024-204707

Published: 2024

Journal Articles

Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Efstathios Kastritis, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2024-209915

Published: 2024

Journal Articles

Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging

Efstathios Kastritis, Panagiotis Malandrakis, Irene Solia, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Christine-Ivy Liacos, Nefeli Mavrianou Koutsoukou, Katerina Chrisostomidou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos

Blood (2024) 144 (Supplement 1): 4675.

https://doi.org/10.1182/blood-2024-203858

Published: 2024

Journal Articles

Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Maria Roussou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Irene Solia, Asimina Papanikolaou, Charikleia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4674.

https://doi.org/10.1182/blood-2024-203780

Published: 2024

Journal Articles

Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Blood (2024) 144 (Supplement 1): 4673.

https://doi.org/10.1182/blood-2024-203776

Published: 2024

Journal Articles

Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Charalampos Filippatos, Magdalini Migkou, Panagiotis Malandrakis, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2024-202610

Published: 2024

Journal Articles

Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, Vasiliki Spiliopoulou, Despina Fotiou, Foteini Theodorakakou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 361.

https://doi.org/10.1182/blood-2024-209826

Published: 2024

Journal Articles

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Meletios-Athanasios Dimopoulos, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1948.

https://doi.org/10.1182/blood-2024-203910

Published: 2024

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Panagiotis Malandrakis, Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Irene Solia, Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Kostantina Taouxi, Alexandra Papadimou, Christine-Ivy Liacos, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2024-203751

Published: 2024

Journal Articles

Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

Blood (2024) 144 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2024-203519

Published: 2024

Journal Articles

An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Maria Douvali, Stavros Gkolfinopoulos, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6720.

https://doi.org/10.1182/blood-2023-173072

Published: 2023

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Blood (2023) 142 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2023-188538

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Efstathios Kastritis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Hariklia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos

Blood (2023) 142 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2023-189521

Published: 2023

NARROW

Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma

Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes

A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

Bone Disease Burden Does Not Seem to Impact Overall Survival in Newly Diagnosed Patients with Multiple Myeloma - a Detailed Imaging Analysis on 119 Patients

Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group

Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma

Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging

Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis

Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only